Eculizumab Ä¡·á·Î È£ÀüµÈ ºñÁ¤Çü ¿ëÇ÷¿äµ¶ÁõÈıº 1¿¹
Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab
±èÁ¤Çö, ÇÑ¿ø°æ, ÃÖÀ¯¹ü, ±èÇüÁ¾, ¿ÀÁö¼ö, ¿Àµµ¿¬, Á¤¼Ò¿µ,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÁ¤Çö ( Kim Jung-Hyun )
Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø ³»°ú
ÇÑ¿ø°æ ( Han Won-Kyung )
Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø ³»°ú
ÃÖÀ¯¹ü ( Choi Yu-Bum )
Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø ³»°ú
±èÇüÁ¾ ( Kim Hyung-Jong )
Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø ³»°ú
¿ÀÁö¼ö ( Oh Ji-Su )
Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø ³»°ú
¿Àµµ¿¬ ( Oh Do-Yeun )
Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø ³»°ú
Á¤¼Ò¿µ ( Chong So-Young )
Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø ³»°ú
Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare syndrome characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal injury, which results from uncontrolled complement activation. Delayed diagnosis and treatment of aHUS may result in end-stage renal disease (ESRD) and an associated dependence on dialysis. In extreme cases, it may cause death due to multi-organ failure. Eculizumab, a humanized monoclonal antibody against C5, inhibits the formation of the terminal membrane attack complex and is used to treat aHUS. Here, we report a 46-year-old male patient who suffered from aHUS relapse, despite prior treatment with repeated plasma exchange and hemodialysis. Eculizumab therapy improved his hematologic findings without use of hemodialysis.
Å°¿öµå
Atypical hemolytic uremic syndrome; Eculizumab
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸